This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?
Tegsedi can significantly delay disease progression, and it is the first subcutaneous treatment to target the disease at its source.1
With Tegsedi, patients have the independence to self-administer at a time and place that works for them.1
For your hATTR patients with stage 1 or 2 polyneuropathy. The priority isn’t only what lies ahead. It’s defending what is still here.
This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?